GlassScriptPhysician profile
Ramesh Brahmbhatt
NPI 1750489977
$23,704.96
in general payments reported to CMS, 2019-2025
25 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $873 · 2021: $1,756 · 2022: $544 · 2023: $198 · 2024: $31.28 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17,945.46 | 2019-2022 | |
| Boston Scientific Corporation | $1,318.45 | 2019-2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $501.30 | 2019-2021 | |
| Abiomed | $469.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.83 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $369.33 | 2019-2021 | |
| United Therapeutics Corporation | $340.87 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $339.00 | 2019-2025 | Opdivo, Camzyos |
| Esperion Therapeutics, INC. | $287.72 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $253.78 | 2021-2022 | |
| Pfizer INC. | $243.45 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $169.64 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.97 | 2019-2022 | |
| Amarin Pharma, INC. | $146.49 | 2019-2022 | |
| Lundbeck LLC | $142.63 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $123.52 | 2022 | |
| Amgen INC. | $89.90 | 2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $84.76 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $81.98 | 2019 | |
| Janssen Scientific Affairs, LLC | $74.50 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.99 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $54.21 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.02 | 2022-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.55 | 2025 | Xifaxan |
| Medtronic Vascular, INC. | $14.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Brahmbhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.